ABEO
Abeona Therapeutics Inc.
Biotechnology · Healthcare · United States
6.35
close · 2026-08-13
value
25
cheaper than peers25
quality
70
stronger fundamentals70
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
caveat reports profit, burns cash
Value inputs
| measure | company | vs peers |
| earnings yield, latest year | 15.9% | 95 |
| price to book | 2.49× | 78 |
| forward P/E | 22.13× | 45 |
| price to sales | 23.72× | 35 |
| cash flow yield, latest year | -23.3% | 23 |
| earnings yield, 1 year ago | -24.4% | 23 |
| cash flow yield, 1 year ago | -16.2% | 23 |
| cash flow yield, 3 years ago | -12.1% | 14 |
| cash flow yield, 2 years ago | -10.3% | 14 |
| earnings yield, 2 years ago | -39.9% | 14 |
| earnings yield, 3 years ago | -87.2% | 5 |
11 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 71.0% | 95 |
| debt to equity | 16.0% | 53 |
| operating margin | -264.1% | 32 |
3 of 4 measures available
Facts
| market cap | $362M |
| free cash flow | -$56.6M |
| employees | 226 |
| first trade | 1980-09-19 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-07-26 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.01 | -1.55 | -2.53 | -5.53 |
| free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M |
| net income | $71.2M | -$63.7M | -$54.2M | -$39.7M |
| revenue | $5.8M | $0 | $3.5M | $1.4M |
| unusual items | $6.1M | -$755,000 | -$10.6M | $5.7M |